MX2021014116A - Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents

Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).

Info

Publication number
MX2021014116A
MX2021014116A MX2021014116A MX2021014116A MX2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A MX 2021014116 A MX2021014116 A MX 2021014116A
Authority
MX
Mexico
Prior art keywords
compounds
purinoreceptor
inhibitors
pyrido
pyrimidine derivatives
Prior art date
Application number
MX2021014116A
Other languages
English (en)
Spanish (es)
Inventor
Matteo Biagetti
Roberta Lanaro
Claudio Fiorelli
Paolo Bruno
Charles Baker-Glenn
De Poël Hervè Van
Stephen David Penrose
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021014116A publication Critical patent/MX2021014116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021014116A 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3). MX2021014116A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19177610 2019-05-31
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
MX2021014116A true MX2021014116A (es) 2021-12-10

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014116A MX2021014116A (es) 2019-05-31 2020-05-28 Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).

Country Status (11)

Country Link
US (1) US12606562B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976609A1 (cg-RX-API-DMAC7.html)
JP (1) JP7797204B2 (cg-RX-API-DMAC7.html)
KR (1) KR102923602B1 (cg-RX-API-DMAC7.html)
CN (1) CN114222741B (cg-RX-API-DMAC7.html)
AU (1) AU2020281924B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020279A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136024A1 (cg-RX-API-DMAC7.html)
MA (1) MA56020A (cg-RX-API-DMAC7.html)
MX (1) MX2021014116A (cg-RX-API-DMAC7.html)
WO (1) WO2020239953A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56022A (fr) 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
JP2026517300A (ja) 2023-05-22 2026-05-28 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ P2x3阻害剤を調製するための方法および中間体
WO2026143058A1 (en) * 2024-12-23 2026-07-02 Neolaia Inc. Pyridopyrimidine compounds useful as cd38 inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
PT1725540E (pt) 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
WO2007134986A1 (en) 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
WO2009110985A2 (en) 2008-02-29 2009-09-11 Renovis, Inc. Amide compounds, compositions and uses thereof
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
JP2012504157A (ja) 2008-09-30 2012-02-16 アストラゼネカ アクチボラグ 複素環式jakキナーゼ阻害剤
SG173647A1 (en) 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
WO2012064973A2 (en) * 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2938600B1 (en) 2012-12-27 2017-01-25 F. Hoffmann-La Roche AG Comt inhibitors
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016084922A1 (ja) 2014-11-28 2016-06-02 塩野義製薬株式会社 1,2,4-トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
CU24411B1 (es) 2014-12-09 2019-05-03 Bayer Ag Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
EP3380469B1 (en) * 2015-11-25 2022-03-16 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
CN106565684B (zh) 2016-03-18 2019-06-18 南方医科大学 6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
JP6776378B2 (ja) 2016-06-30 2020-10-28 ギリアード サイエンシーズ, インコーポレイテッド Cotモジュレーターとしての4,6−ジアミノキナゾリン類およびその使用方法
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
DK3827005T3 (da) * 2018-07-25 2022-09-19 Faes Farma Sa Pyridopyrimidiner som histamin H4-receptorhæmmere
CN109721554A (zh) 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
MA56022A (fr) * 2019-05-31 2022-04-06 Chiesi Farm Spa Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR102923602B1 (ko) 2019-05-31 2026-02-06 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 피리도피리미딘 유도체

Also Published As

Publication number Publication date
BR112021020279A2 (pt) 2021-12-14
US20220235060A1 (en) 2022-07-28
CN114222741B (zh) 2025-12-30
EP3976609A1 (en) 2022-04-06
JP2022534434A (ja) 2022-07-29
WO2020239953A1 (en) 2020-12-03
AU2020281924B2 (en) 2026-04-16
KR102923602B1 (ko) 2026-02-06
MA56020A (fr) 2022-04-06
US12606562B2 (en) 2026-04-21
AU2020281924A1 (en) 2021-12-16
KR20220016074A (ko) 2022-02-08
US20230212169A9 (en) 2023-07-06
CA3136024A1 (en) 2020-12-03
JP7797204B2 (ja) 2026-01-13
CN114222741A (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
CO2021017031A2 (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3)
MX393050B (es) Derivados de amida de tirosina como inhibidores de rho-cinasa.
BR112021020279A2 (pt) Derivados de piridopirimidinas como inibidores de p2x3
DOP2021000019A (es) Inhibidores de inflamasoma nlrp3
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CL2020002939A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
BR112015009486A2 (pt) surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
CR20140516A (es) Compuestos de pirazol sustituidos como antagonistas de lpar
BR112023004612A2 (pt) Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-acetamida como inibidores de receptor i de fator-beta de crescimento transformador/alk5
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
CO2021001174A2 (es) Inhibidores de ckd8/19
MX2023005803A (es) Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005865A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
EA202193300A1 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
CO2023009444A2 (es) Derivados de dihidrofuropiridina como inhibidores de la rho-cinasa
MX377199B (es) Nuevo compuesto aislado a partir de pseudolysimachion rotundum var. subintegrum que contiene cantidades abundantes del ingrediente activo, la composicion que lo comprende para prevenir o tratar la enfermedad alergica, enfermedad inflamatoria, asma o enfermedad pulmonar obstructiva cronica y el uso del mismo.
UY38550A (es) Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados